ARNA - ARNA STOCK NEWS

Arena Pharmaceuticals (Nasdaq: ARNA) will present data from its Phase 2b ADVISE trial on etrasimod, an oral S1P receptor modulator for moderate-to-severe atopic dermatitis, at the American Academy of Dermatology Virtual Meeting from April 23-25, 2021. The study aims to demonstrate improvements in patient and clinician-reported outcomes. Etrasimod, still investigational and not yet approved, targets multiple immune-mediated inflammatory diseases including atopic dermatitis, ulcerative colitis, and Crohn's disease.

Arena Pharmaceuticals (Nasdaq: ARNA) announced on April 15, 2021, the grant of inducement stock options and restricted stock units (RSUs) to 17 new employees. The total includes 50,785 stock options and 20,490 RSUs, with a grant date and vesting commencement on April 15, 2021. The stock options have a seven-year term with an exercise price of $67.99 per share and vesting over four years. The RSUs also vest over four years, with a similar structure. These grants comply with Nasdaq Listing Rule 5635(c)(4).

Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options, performance restricted stock units (PRSUs), and restricted stock units (RSUs) to new employees as per Nasdaq Listing Rule 5635(c)(4). The options include 40,000 shares to Mike Paolucci, 12,900 shares to four new employees, and 5,595 RSUs. The stock options have a seven-year term with an exercise price of $77.58 and vesting over four years. PRSUs will vest based on the stock price reaching specific thresholds by February 2024. This initiative aims to attract talent and align employee interests with company performance.

Arena Pharmaceuticals (Nasdaq: ARNA) announced topline results from the Phase 2b CAPTIVATE trial of olorinab, a cannabinoid receptor 2 (CB₂) full agonist, in patients with abdominal pain from Irritable Bowel Syndrome (IBS). The study included 273 participants and showed that while olorinab was well tolerated, it did not fulfill its primary efficacy endpoint. However, a subgroup with moderate to severe pain (50% of participants) experienced a statistically significant reduction in pain scores with the 50 mg dose. No serious adverse events were reported, suggesting a favorable safety profile.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported its fourth quarter and full year 2020 financial results. The company noted the completion of enrollment for the ELEVATE UC 52 trial and initiated the Phase 2b VOYAGE trial for etrasimod. Despite advancements, revenues for Q4 were zero compared to $3.0 million last year, while net loss increased to $122.2 million. R&D expenses surged to $100.4 million, reflecting ongoing clinical studies. The company maintains a strong cash position of approximately $1.1 billion, supporting its diverse pipeline.

Arena Pharmaceuticals (Nasdaq: ARNA) announced on February 15, 2021, the granting of inducement stock options for 33,885 shares and 8,475 restricted stock units (RSUs) to eleven new employees. The stock options have a seven-year term, an exercise price of $83.95 per share, and vest over four years. RSUs also vest over four years, with a similar structure for timing and conditions. These grants are made in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to encourage new hires to join Arena’s team.

Arena Pharmaceuticals (Nasdaq: ARNA) will announce its Q4 and full-year 2020 financial results on February 23, 2021, after U.S. market close. A conference call and live webcast for investors will take place on the same day at 4:30 PM ET. Interested parties can join by dialing (877) 643-7155 for the U.S. or (914) 495-8552 internationally, using conference ID 1778476. A replay will be available for 30 days. The company is committed to delivering essential medicines, focusing on stakeholder needs and innovative solutions.

Arena Pharmaceuticals (Nasdaq: ARNA) has appointed Garry Neil, MD, as Chair of the Board and Nawal Ouzren as a new Board member. These changes aim to enhance the company’s leadership and positioning for anticipated growth. Dr. Neil has extensive experience in the pharmaceutical industry and previously served in senior roles at significant companies like Johnson & Johnson. Ouzren brings 20 years of expertise in clinical development and operations from her roles at Sensorion SAS and Shire International. CEO Amit D. Munshi emphasized that these appointments mark a pivotal moment in Arena's growth trajectory.

Arena Pharmaceuticals (Nasdaq: ARNA) has successfully completed enrollment for the Phase 3 ELEVATE UC 52 trial, focusing on etrasimod's efficacy in treating moderately-to-severely active ulcerative colitis. The trial, which includes 433 participants across 40 countries, aims to assess clinical remission at 12 and 52 weeks. Topline data from both ELEVATE UC 52 and UC 12 trials is expected in Q1 2022. Etrasimod is a potential treatment for various immune-mediated inflammatory diseases but is currently an investigational compound lacking regulatory approval.